CCONNECTA Therapeutics
Barcelona-based clinical-stage biotech developing novel treatments for central nervous system (CNS) disorders with unmet medical needs, spun off from Prous Institute for Biomedical Research in 2019. Lead asset CTH120 is a first-in-class neuroplasticity modulator being developed for fragile X syndrome and other neurodevelopmental conditions; the company reported positive Phase I results and began Phase IIa trials in 2026, backed by a €2.5M EIC Accelerator grant.
SectorsHealthtech & Bio, Biotechnology, CNS/Neuroscience, Drug Discovery
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
J
Jordi Fàbrega
Co-Founder, CEO & Board Member
J
Josep Prous Jr.
Co-Founder, CSO & Board Member
Global models 5
NNeumora Therapeutics
United States · neumoratx.com ↗
Clinical-stage biotech developing new small-molecule drugs for brain disorders with high unmet need, funded by venture capital until it goes public or partners its drugs.
$600M+Comparable
CCerevel Therapeutics
United States · cerevel.com ↗
Venture-built CNS drug developer that took compounds through clinical trials and made its money through a sale to AbbVie, the same asset-to-exit model.
$350M+Comparable
RRapport Therapeutics
United States · rapportrx.com ↗
Clinical-stage neuroscience biotech developing precision drugs for neurological disorders, funded by VC ahead of licensing deals or an IPO.
$250MComparable
PPraxis Precision Medicines
United States · praxismedicines.com ↗
VC-backed CNS biotech whose early pipeline targeted neurodevelopmental and genetic brain disorders, taking first-in-class drugs from Phase I into Phase II.
$190MComparable
HHealx
United Kingdom · healx.ai ↗
European clinical-stage biotech whose lead programme is in fragile X syndrome, developing drugs to license or partner with pharma, the same model and target condition.
$115MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 5
Open as list →
IInveready
www.inveready.com
CClave Capital
clavemayor.com
CCentro para el Desarrollo Tecnológico y la Innovación
www.cdti.es
D
David Prous
PProus Institute for Biomedical Research
Funding rounds 2
·1 not counted| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-09-10 | Series A | €3.1M |
Clave Capital
+3 more
|
| 2020-09-28 | Seed (estimated) | €1.7M |
Inveready
+4 more
|